Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 398 participants.

Also called NCT05199194

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 398 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05199194
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05199194. Randomized; quadruple masking; primary purpose treatment. Start 2022-05-27 (actual); primary completion 2026-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke
Acronym
DIRECT-TNK
Condition
Stroke, Ischemic
Condition
Stroke, Acute
Intervention (Drug)
Tenecteplase
Intervention (Drug)
Placebo
Lead sponsor
Hospital Moinhos de Vento (class: other)
Collaborator
Ministry of Health, Brazil (class: other government)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
Medtronic (class: industry)

Record details

Record id
cardio:ct-nct05199194
Content hash
61611317ddd6b32fa2142f6232f8b8f684564a9c819309a873c691360498bdb2